ArticleJournal of the International Association of Providers of AIDS Care
Health Care Providers' Experiences With and Perceived Barriers to Implementation of Long-Acting Injectable HIV Preexposure Prophylaxis: A Cross-Sectional Survey.
Article in Journal of the International Association of Providers of AIDS Care. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
IntroductionLong-acting injectable cabotegravir (CAB-LA) is highly efficacious as PrEP and could increase PrEP coverage, though uptake has been limited.MethodsWe surveyed healthcare professionals regarding experiences with CAB-LA implementation in the United States. We used descriptive statistics to summarize perceived barriers and Fisher's exact tests to assess for factors associated with CAB-LA availability and use.ResultsAmong respondents, 71% (51/72) reported their clinic site offered CAB-LA though only 44% (20/45) reported having prescribed it. The most common perceived barriers were concerns about insurance coverage (38/45, 84%), logistics (35/45, 78%), lack of requests (32/45, 71%), concern for missed injections (17/25, 68%), and cost (16/25, 64%). A majority (30/45, 67%) felt that lack of training was a barrier. Availability and prescribing did not vary by demographic or patient panel characteristics (p-values>0.05).ConclusionsHealthcare professionals' perceived barriers to CAB-LA uptake suggest need for improved implementation strategies, specifically surrounding cost, logistics, and education.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.